Digest Network Come funziona
Network
/
Società
Za
Non verificato

Zai Lab Limited

Di cosa scriviamo

BiotecnologiaFarmaceuticaOncologiaSaluteScienza

74 comunicati stampa

Guarda tutti i comunicati
17/08/2026
Industria
Biotecnologia
Farmaceutica
Salute
Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
Fonte
Zai Lab Limited
Emittente
Business Wire
1.00
0
06/08/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Oncologia
Salute
HIV, AIDS e malattie autoimmuni
Farmaceutica
Biotecnologia
Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates
Fonte
Zai Lab Limited
Emittente
Business Wire
1.00
0
03/08/2026
Oncologia
Igiene alimentare
Salute
HIV, AIDS e malattie autoimmuni
Farmaceutica
Biotecnologia
U.S. FDA Grants Orphan Drug Designation to Zai Lab’s DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs)
Fonte
Zai Lab Limited
Emittente
Business Wire
1.00
0
22/07/2026
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Biotecnologia
Salute
Farmaceutica
Oncologia
Zai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026
Fonte
Zai Lab Limited
Emittente
Business Wire
1.00
0
16/06/2026
Industria
Igiene alimentare
Medicina - Varie
Biotecnologia
Medicina nucleare
Salute
Farmaceutica
Sanità
Oncologia
Zai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine Carcinomas
Fonte
Zai Lab Limited
Emittente
Business Wire
1.00
0
09/06/2026
Industria
Oncologia
Salute
Sanità
Medicina nucleare
Medicina - Varie
Farmaceutica
Biotecnologia
Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer
Fonte
Zai Lab Limited
Emittente
Business Wire
1.00
0
21/05/2026
Mercato del lavoro
Oncologia
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Farmaceutica
Biotecnologia
Zai Lab Announces Changes to Senior Leadership Team
Fonte
Zai Lab Limited
Emittente
Business Wire
1.00
0
11/05/2026
Eventi
Industria
Igiene alimentare
Medicina - Varie
Biotecnologia
Medicina nucleare
Salute
Farmaceutica
Sanità
Oncologia
Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)
Fonte
Zai Lab Limited
Emittente
Business Wire
1.00
0
07/05/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Oncologia
Salute
HIV, AIDS e malattie autoimmuni
Farmaceutica
Biotecnologia
Zai Lab Announces First Quarter 2026 Financial Results and Recent Corporate Updates
Fonte
Zai Lab Limited
Emittente
Business Wire
1.00
0
22/04/2026
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
HIV, AIDS e malattie autoimmuni
Zai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026
Fonte
Zai Lab Limited
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0